Physician profile
Jesse Gordon
NPI 1891923595
$5,448.51
in general payments reported to CMS, 2019-2025
24 companies · $937 in 2025
The $937 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $278 · 2021: $580 · 2022: $756 · 2023: $1,558 · 2024: $1,340 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,858.03 | 2020-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $1,648.30 | 2021-2025 | Biktarvy, Yeztugo, Epclusa |
| Abbvie INC. | $625.65 | 2021-2025 | |
| Boston Scientific Corporation | $191.53 | 2020 | |
| Antares Pharma, INC. | $153.98 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $131.05 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $102.87 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $101.58 | 2021-2025 | Pifeltro, Delstrigo |
| Janssen Biotech, INC. | $99.42 | 2023 | Symtuza |
| Indivior INC. | $79.24 | 2021-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $79.05 | 2020-2021 | |
| Theratechnologies INC. | $74.96 | 2021-2023 | Trogarzo, Egrifta |
| Otsuka America Pharmaceutical, INC. | $64.61 | 2022-2024 | Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $52.47 | 2022-2024 | Ozempic, Rybelsus |
| Janssen Products, LP | $31.49 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $23.89 | 2023 | Lybalvi |
| Verity Pharmaceuticals INC. | $18.92 | 2024 | Tlando |
| Halozyme INC | $18.25 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.32 | 2021 | |
| Braeburn INC. | $16.90 | 2024 | Brixadi |
| Organon LLC | $16.16 | 2023 | Nexplanon |
| Hologic Sales and Service, LLC | $15.74 | 2025 | Aptima |
| Dynavax Technologies Corporation | $14.36 | 2022 | |
| Neurocrine Biosciences, INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.